Literature DB >> 18174782

Hypertension control in the elderly.

Joel M Neutel1, Lawrence I Gilderman.   

Abstract

Hypertension is highly prevalent in older persons and most often presents as isolated systolic hypertension. Systolic blood pressure (BP) is a stronger predictor of risk than diastolic BP in persons older than 50 years. Most of these patients will require multiple drug therapies to achieve the substantial reductions in systolic BP needed to reach target levels. Clinical trials have demonstrated that antihypertensive therapy with beta-blockers and diuretics as well as with calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II type 1 receptor blockers reduces cardiovascular risk in older patients. Studies examining safety and BP-lowering efficacy have shown that a renin-angiotensin-aldosterone system blocker plus a calcium channel blocker as well as a combination of diuretics and beta-blockers or diuretics plus an angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker achieves greater BP reductions than monotherapy. Such multiple drug regimens are well tolerated in older patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174782      PMCID: PMC8110161          DOI: 10.1111/j.1524-6175.2007.08030.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  46 in total

Review 1.  Drug therapy in the elderly.

Authors:  Klaus Turnheim
Journal:  Exp Gerontol       Date:  2004 Nov-Dec       Impact factor: 4.032

Review 2.  Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect.

Authors:  Peter A Meredith
Journal:  Am J Cardiovasc Drugs       Date:  2005       Impact factor: 3.571

3.  Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III.

Authors:  S S Franklin; M J Jacobs; N D Wong; G J L'Italien; P Lapuerta
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

4.  Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.

Authors:  S S Franklin; M G Larson; S A Khan; N D Wong; E P Leip; W B Kannel; D Levy
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

5.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 6.  How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure.

Authors:  V Singh; J Christiana; W H Frishman
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

7.  Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

Authors:  Kwok Leung Ong; Bernard M Y Cheung; Yu Bun Man; Chu Pak Lau; Karen S L Lam
Journal:  Hypertension       Date:  2006-12-11       Impact factor: 10.190

8.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jose Luis Zamorano; Sverre E Kjeldsen; Serap Erdine; Krzysztof Narkiewicz; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Renata Cifkova; Anna Dominiczak; Robert Fagard; Anthony M Heagerty; Stephane Laurent; Lars H Lindholm; Giuseppe Mancia; Athanasios Manolis; Peter M Nilsson; Josep Redon; Roland E Schmieder; Harry A J Struijker-Boudier; Margus Viigimaa; Gerasimos Filippatos; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Wolfgang Kiowski; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Margus Viigimaa; Bernard Waeber; Bryan Williams; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2007-06-11       Impact factor: 29.983

9.  Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial.

Authors:  Jan A Staessen; Lutgarde Thijisq; Robert Fagard; Hilde Celis; Willem H Birkenhäger; Christopher J Bulpitt; Peter W de Leeuw; Astrid E Fletcher; François Forette; Gastone Leonetti; Patricia McCormack; Choudomir Nachev; Eoin O'Brien; José L Rodicio; Joseph Rosenfeld; Cinzia Sarti; Jaakko Tuomilehto; John Webster; Yair Yodfat; Alberto Zanchetti
Journal:  J Hypertens       Date:  2004-04       Impact factor: 4.844

Review 10.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

View more
  4 in total

1.  Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study.

Authors:  Joel Neutel; Dean J Kereiakes; Kathy A Stoakes; Jen-Fue Maa; Ali Shojaee; William F Waverczak
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.

Authors:  David A Calhoun; Yves Lacourcière; Nora Crikelair; Yan Jia; Robert D Glazer
Journal:  Curr Med Res Opin       Date:  2013-07-01       Impact factor: 2.580

3.  Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex.

Authors:  Suzanne Oparil; Eduardo Pimenta
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-01       Impact factor: 3.738

4.  The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older.

Authors:  Dean J Kereiakes; Joel Neutel; Kathy A Stoakes; William F Waverczak; Jianbo Xu; Ali Shojaee; Robert Dubiel
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-08       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.